65,437 trials
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 — -0.51; -0.16 Percent of glycosylated haemoglobin — p=<0.0001
Coronary Artery Disease
Primary: TLF (Target Lesion Failure) Rate — 4.4 percentage of participants with TLF
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Viral Response 12 Weeks After Completing Study Therapy (SVR12) — 90.0; 100.0 Percentage of participants
Inflammation · Barrett's Esophagus
Primary: Change in Inflammation Biomarker Tissue PGE2 Level — 1.35; -0.02; 1.19; -0.06 nanograms/gram of tissue — p=0.30
Unresectable Stage III · Stage IV Melanoma
Primary: Objective Response Rate (ORR) — 8.6; 9.0 Percentage of participants
Atherosclerotic Lesion(s)
Primary: In-stent Late Loss — 0.23 mm
Preterm Birth
Primary: Infant Gestational Age — 38.14; 38.14 weeks — p=.64
Atrial Fibrillation or Atrial Flutter
Primary: Atrial Fibrillation Dominant Frequency
Morbid Obesity
Primary: Decrease in the Visceral Fat Layer Measured by Ultrasound a Day Before and a Year After Surgery. — 3.6; 7.1; 5.6 visceral fat reduction in centimeters
P Acnes Colonization
Primary: Change From Baseline in Quantitative Bacteriology Measurements at Week 4 — -1.6 log10 CFU/cm2
Acne Vulgaris
Primary: Percent Change From Baseline in Total Lesion Counts — -47; -64 Percent Change
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Percentage of Participants Reporting Safety and Tolerability in Terms of Adverse Event (AE) Reporting Rate — 77.3; 77 Percentage of participants
Bacterial Infections · Virus Diseases
Primary: Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen — 84.97; 75.39; 97.25; 92.41 Percentage of participants — p=<0.001
Prostate Cancer
Primary: Overall Survival (OS) — 11.04; 10.02 months — p=0.0127
Kidney Cancer
Primary: Successful Capture of IO-CEUS Images — 10 participants